Align Technology (ALGN)
(Delayed Data from NSDQ)
$219.70 USD
+3.68 (1.70%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $219.71 +0.01 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$219.70 USD
+3.68 (1.70%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $219.71 +0.01 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth C Momentum D VGM
Zacks News
Medical Product Earnings Lineup for Jul 25: TMO, BSX & More
by Zacks Equity Research
The Medical product market further gains momentum on the back of a recent two-year suspension of the controversial 2.3% Medical Device tax.
Quest Diagnostics (DGX) Q2 Earnings Meet, Guidance Narrowed
by Zacks Equity Research
Quest Diagnostics (DGX) gains on successful execution of its two-point strategy of accelerating growth and driving operational excellence in Q2.
Is a Surprise Coming for Align Technology (ALGN) This Earnings Season?
by Zacks Equity Research
Align Technology (ALGN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Merit Medical (MMSI) Beats on Q2 Earnings, Raises Guidance
by Zacks Equity Research
Merit Medical (MMSI) gains from solid segmental performance in Q2; lifts 2018 guidance.
PetMed (PETS) Q1 Earnings Lag Estimates, Reorder Sales Solid
by Zacks Equity Research
We are encouraged by growth in PetMed's (PETS) reorder and new order sales in Q1. Increased online sales buoy optimism.
Can Overall Growth Drive ResMed's (RMD) Q4 Earnings?
by Zacks Equity Research
ResMed (RMD) is likely to keep its winning streak alive with a gain from strong performances on the domestic as well as global front in Q4.
Can CAG Growth Continue to Aid IDEXX (IDXX) in Q2 Earnings?
by Zacks Equity Research
IDEXX (IDXX) is enhancing its commercial capabilities in the United States to maintain recurring revenue growth at CAG Diagnostics.
Can Solid Overall Growth Drive Illumina's (ILMN) Q2 Earnings?
by Zacks Equity Research
Illumina (ILMN) to gain from strong revenues at the Product, Service and other segments in Q2.
Molecular Diagnostics to Aid Hologic's (HOLX) Q3 Earnings
by Zacks Equity Research
Strength in the Panther system and increasing utilization of Aptima women's health assays will boost Hologic's (HOLX) molecular diagnostics in Q3.
Top Ranked Momentum Stocks to Buy for July 23rd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 23rd:
What's in Store for Universal Health's (UHS) Q2 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q2 is likely to benefit from strong performances at its Acute Care and Behavioral Health segments.
What's in the Cards for HCA Healthcare (HCA) in Q2 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) Q2 results are likely to be aided by a strong top line, riding on higher admissions, partially offset by increasing costs.
What's in Store for GNC Holdings (GNC) This Earnings Season?
by Zacks Equity Research
GNC Holdings' (GNC) revenues are likely to decline on a year-over-year basis, owing to weakness in U.S. & Canada segments in Q2.
Here's Why You Should Add Abbott (ABT) to Your Portfolio Now
by Zacks Equity Research
We are upbeat about Abbott's (ABT) synergies from Alere buyout in the form of solid Rapid Diagnostics revenues. Emerging market performance has been promising.
Should iShares Morningstar Mid-Cap Growth ETF (JKH) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKH
Intuitive Surgical (ISRG) Beats on Q2 Earnings & Revenues
by Zacks Equity Research
Strong performance in the Instruments & Accessories as well as Systems segments drove Intuitive Surgical's (ISRG) top line in Q2.
Neogen (NEOG) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Neogen (NEOG) sticks to its four-pronged growth strategy for steady progress. Also, the company's accretive buyouts and its broader international base are a boon.
Is a Beat in the Cards for Centene (CNC) in Q2 Earnings?
by Zacks Equity Research
Centene's (CNC) Q2 earnings is likely to gain from higher membership and revenues from Government business.
Is Align Technology (ALGN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ALGN) Outperforming Other Medical Stocks This Year?
Has Align Technology (ALGN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ALGN) Outperforming Other Medical Stocks This Year?
Can Solid Global Prospects Drive Align's (ALGN) Q2 Earnings?
by Zacks Equity Research
Align Technology (ALGN) poised to gain on continued strength in all geographies in Q2.
Will Edwards' (EW) Steady Overall Growth Drive Q2 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) expected to gain from strength in all business segments and geographies in Q2.
S&P 500 at 5-Month High: 5 Stocks Up More Than 45%
by Sweta Killa
Given that S&P 500 is at 5-month high, we have presented a bunch of stocks that have easily led the way on the index gaining more than 45% in the same time frame.
Stock-Picking is a Cult
by Kevin Cook
A plea to Millennials to learn the greatest, most fascinating game on the planet.
Abbott (ABT) Q2 Earnings & Revenues Top Estimates, View Up
by Zacks Equity Research
Abbott (ABT) posts another quarter of strong EPD and Medical Devices performance. Particularly, Abbott has been riding high on a healthy growth within its Diabetes Care business.